Fezolinetant - CISMeF

Preferred Label : Fezolinetant;

NCIt definition : An orally bioavailable, neurokinin/tachykinin 3 receptor (NK1-receptor; NK3R; NK-3R) antagonist, that can be used to treat vasomotor symptoms (VMS) in menopausal woman. Upon oral administration, fezolinetant targets, competitively binds to and blocks the activity of NK3R in the central nervous system (CNS). Specifically, this blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDgamma) neuron in the thermoregulatory center and inhibits NK3R-mediated signal transduction. This prevents VMS. Neurokinin-mediated signaling may increase during hormone deficiency and may cause VMS.;

UNII : 83VNE45KXX;

InChIKey : PPSNFPASKFYPMN-SECBINFHSA-N;

CAS number : 1629229-37-3;

Drug name : Veozah;

Molecule name : A-2693; ESN-364; ESN 364; AS 3472693-00; ES 256364; ES-256364; A 2693; AS3472693-00;

NCI Metathesaurus CUI : CL1406030;

Détails

Origin ID

C171845;

UMLS CUI

C4547455;

Currated CISMeF NLP mapping
- Fezolinetant [SMS substance]
- fezolinetant [MeSH concept]
- fezolinetant [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- fezolinetant [MeSH Supplementary Concept]
- fezolinetant [ATC Code]
Validated automatic mappings to BTNT
- fezolinetant [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Neuromedin-K Receptor [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients